The Guideline

The Guideline

• 1: Development and Implementation
  • Medical Evidence
  • Strength of Recommendation
  • Guideline Development
  • Summary
  • Appendix A
  • Appendix C
  • References
• 2: Working Definition
  • Additional Definitions
  • Appendix B
  • References
• 3: Prevention
  • Patients with Risk Factors
  • References
• 4: Evaluation of Ventricular Dysfunction
  • Evaluation of Patients at Risk
  • Evaluation of Patients Suspected of Having Heart Failure
  • Common Errors in Initial Assessment
  • References
• 5: Asymptomatic Patients
  • Recommendations
  • Device Therapies in Patients With ALVD
  • References
• 6: Nonpharmacologic Management
  • Diet and Nutrition
  • Other Therapies
  • Specific Activity and Lifestyle Issues
  • Health Care Maintenance Issues
  • Exercise Rehabilitation as Therapy for HF
  • Potential Pathophysiologic Role of Hemoglobin in HF
  • References
• 7: Reduced Ejection Fraction
  • ACE Inhibitors
  • Beta Adrenergic Receptor Blockers
  • Implantation of Cardiac Pacemakers in Patients With Baseline Bradycard
  • Angiotensin Receptor Blockers
  • Aldosterone Antagonists
  • Renin Inhibitors
  • Oral Nitrates and Hydralazine
  • Optimal Use of Multi-Drug Therapy
  • Diuretic Therapy
  • Digoxin
  • Anticoagulation and Antiplatelet Drugs
  • Amiodarone Therapy
  • Polyunsaturated Fatty Acids
  • References
• 8: Disease Management, Advance Directives, End-of-Life Care
  • Education and Counseling
  • Disease Management Programs
  • Advance Directives and End-of-Life Care
  • References
• 9: EP Testing and Use of Devices
  • EP Testing and Evaluation of Syncope
  • Prophylactic ICD Placement
  • Biventricular Resynchronization Pacing
  • Dual Chamber Pacemakers
  • References
• 10: Surgical Approaches
  • Emerging Surgical Techniques
  • References
• 11: Preserved LVEF
  • Recommendations
  • References
• 12: Acute Decompensated HF
  • Diagnosis
  • Hospital Admission
  • Treatment
  • Fluid Overload
  • Prevention of Deep Venous Thrombosis and Pulmonary Embolism
  • IV Vasodilators
  • Hemodynamic Monitoring
  • Precipitating Factors
  • Hospital Discharge
  • References
• 13: Ischemic Heart Disease
  • Prognostic Significance of Underlying CAD Etiology in Patients with HF
  • Evaluation for CAD
  • Therapy for Patients with HF and CAD
  • References
• 14: Hypertension and HF
  • Recommendations
  • References
• 15: HF in Special Populations
  • Elderly Patients with HF
  • HF in Women
  • Evidence for Other Medical Therapy in Women
  • HF in African Americans
  • References
• 16: Myocarditis
  • Recommendations
  • References
• 17: Genetic Evaluation
  • Medical Evidence for Genetic Evaluation
  • Molecular Genetic Testing
  • Genetic Counseling
  • Therapy Based on Genetic Testing
  • Therapy Based on Cardiac Phenotype
  • Pediatric Forms of Inherited Cardiomyopathies
  • References

About the Guideline

• Home
• About
  • Committee Members
  • Author Information
  • Acknowledgment of Support
  • Key Words
  • Abstract
  • Committee Disclosure
• Contact Us
• Career Center
• Search

News & Downloads

• What's New
• Feedback
• Get Updates
• Resources
  • Guideline Sections
  • Slide Sets: All Recommendations
  • Slide Set: Key Recommendations
• Related Links

Legal Information

• ©2010 HFSA
• Disclaimer
• Privacy Policy
• Site Map